Want to see NVCT full AI Analyst Report?
NVCT Stock Chart & Stats
$19.31
$0.12(0.62%)
At close: 4:00 PM EDT
$19.31
$0.12(0.62%)
Day’s Range― - ―
52-Week Range$5.55 - $29.28
Previous CloseN/A
Volume13.30K
Average Volume (3M)89.48K
Market Cap
$678.43M
Enterprise Value$155.86
Total Cash (Recent Filing)$25.13M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Aug 11, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding31,525,534
10 Day Avg. Volume112,705
30 Day Avg. Volume89,483
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)8.94
Price to Sales (P/S)0.00
P/FCF Ratio-10.29
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$31.00Price Target Upside60.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt balance sheet and positive equity materially reduce leverage risk and preserve strategic optionality. Over a multi-month horizon this supports continued R&D investment, lowers bankruptcy risk, and gives management flexibility on financing timing and deal structuring without high interest obligations.
Strengthened Liquidity From Equity OfferingA near-term capital infusion of ~ $93M meaningfully extends runway and reduces immediate funding pressure. This durable change allows the company to advance multiple clinical programs, hire staff, fund capital spending, and reduce the probability of disruptive emergency financing over the next 6–12 months.
Portfolio Expansion Via Haisco LicenseAcquiring clinical-stage NXP100 and NXP200 materially diversifies the pipeline away from single-program risk. NXP100 has regulatory filings and positive Phase 2/3 data in key indications, improving probability-weighted future revenue and positioning the company in high-value complement and BRAF markets over coming years.
Bears Say
Pre-revenue With Widening LossesBeing pre-revenue with accelerating net losses creates a persistent funding requirement and extends time to profitability. Over 2–6 months this structural profile means growth depends entirely on successful clinical progress or financing, increasing execution risk and potential dilution for existing shareholders.
Negative Cash Generation / Rising BurnSustained negative operating and free cash flow reflects an elevated cash burn rate, accelerating the need for capital. Even with recent financing, continued elevated burn could necessitate additional raises, compress management flexibility and delay program milestones if resources are reallocated to preserve liquidity.
Dilution And Milestone/royalty ObligationsEquity issuance reduces existing ownership and can dampen per-share economics; the Haisco license adds contingent milestone and royalty payments that will reduce future gross margins and cash available on commercialization. Together these structurally constrain shareholder upside and add future cash outflow commitments.
Nuvectis Pharma News
NVCT FAQ
What was Nuvectis Pharma’s price range in the past 12 months?
Nuvectis Pharma lowest stock price was $5.55 and its highest was $29.27 in the past 12 months.
What is Nuvectis Pharma’s market cap?
Nuvectis Pharma’s market cap is $678.43M.
When is Nuvectis Pharma’s upcoming earnings report date?
Nuvectis Pharma’s upcoming earnings report date is Aug 11, 2026 which is in 9 days.
How were Nuvectis Pharma’s earnings last quarter?
Nuvectis Pharma released its earnings results on May 05, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.314 by $0.054.
Is Nuvectis Pharma overvalued?
According to Wall Street analysts Nuvectis Pharma’s price is currently Undervalued.
Does Nuvectis Pharma pay dividends?
Nuvectis Pharma does not currently pay dividends.
What is Nuvectis Pharma’s EPS estimate?
Nuvectis Pharma’s EPS estimate is -0.26.
How many shares outstanding does Nuvectis Pharma have?
Nuvectis Pharma has 31,525,534 shares outstanding.
What happened to Nuvectis Pharma’s price movement after its last earnings report?
Nuvectis Pharma reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.314. Following the earnings report the stock price went up 9.224%.
Which hedge fund is a major shareholder of Nuvectis Pharma?
Currently, no hedge funds are holding shares in NVCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvectis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.00 (60.54% Upside)
$31.00 (60.54% Upside)
Blogger Sentiment
Bullish
NVCT Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
82.74%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.76%
Trailing 12-Months
Company Description
Nuvectis Pharma
Nuvectis Pharma, Inc. (NVCT) is a biopharmaceutical company focused on developing precision oncology therapeutics. The company’s pipeline centers on targeted small-molecule drug candidates intended to treat genetically defined cancers, with lead programs including NXP800 (a Heat Shock Factor 1 (HSF1) pathway modulator) and NXP900 (a kinase inhibitor program). Nuvectis is primarily engaged in research and development and, as a clinical-stage company, does not market approved products.
NVCT Stock 12 Month Forecast
Average Price Target
$31.00
▲(60.54% Upside)
Technical Analysis
Nkarta
―
Orchestra BioMed Holdings
―
Greenwich LifeSciences
―
Molecular Partners
―
Pyxis Oncology
―
Ownership Overview
36.00% Insiders
3.74% Mutual Funds
2.72% Other Institutional Investors
51.69% Public Companies and
Individual Investors